According to our (Global Info Research) latest study, the global Isatuximab market size was valued at US$ 648 million in 2025 and is forecast to a readjusted size of US$ 1740 million by 2032 with a CAGR of 13.8% during review period.
Isatuximab is a humanized monoclonal antibody targeting CD38, primarily used in the treatment of hematologic malignancies such as multiple myeloma. It exerts its anti-tumor effects by specifically binding to the CD38 antigen expressed on the surface of tumor cells, thereby inducing multiple immune-mediated mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of tumor cell apoptosis. Isatuximab is typically used in combination with immunomodulatory agents or proteasome inhibitors for patients with relapsed or refractory multiple myeloma, and has significant clinical value in the field of hematologic cancer targeted therapy.In 2025, global Isatuximab production reached approximately 120,000 units.
Isatuximab, as a CD38-targeting monoclonal antibody, holds an important position in the treatment market for multiple myeloma. With the acceleration of global aging and the gradual increase in the incidence of multiple myeloma, the demand for hematologic cancer therapies continues to grow, driving the expansion of the CD38-targeted drug market. Isatuximab has steadily increased its market penetration due to its clinical efficacy in relapsed or refractory patients and its growing use in frontline combination therapy regimens. From a competitive landscape perspective, this field is primarily dominated by early entrants such as daratumumab. However, Isatuximab is gradually gaining market share through differentiated clinical data and combination treatment strategies. Looking ahead, with the approval of more frontline indications, the standardization of combination therapies, and further expansion into global markets, the market size of Isatuximab is expected to maintain steady growth, continuing to play an important role in the CD38-targeted therapy landscape.
This report is a detailed and comprehensive analysis for global Isatuximab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Isatuximab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Isatuximab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Isatuximab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Isatuximab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Isatuximab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Isatuximab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Sanofi Winthrop Industrie, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Isatuximab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Monoclonal Antibody, mAb
Polyclonal Antibody, pAb
Market segment by Specification
100 mg / 5 mL
500 mg / 25 mL
Market segment by Route of Administration
Hospital
Retail
Online
Market segment by Application
Relapsed or Refractory Multiple Myeloma (R/R MM)
Frontline Multiple Myeloma (Frontline MM)
CD38-Positive Hematologic Malignancies
Precision Hematologic Cancer Therapy
Others
Major players covered
Sanofi
Sanofi Winthrop Industrie
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Isatuximab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Isatuximab, with price, sales quantity, revenue, and global market share of Isatuximab from 2021 to 2026.
Chapter 3, the Isatuximab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Isatuximab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Isatuximab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Isatuximab.
Chapter 14 and 15, to describe Isatuximab sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Isatuximab. Industry analysis & Market Report on Isatuximab is a syndicated market report, published as Global Isatuximab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Isatuximab market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.